NEW YORK ( TheStreet) -- Several stocks trading near $5 were poised to move on above-average volume during Monday's session.

Arrowhead Research ( ARWR) climbed by 6 cents, or 11.1%, to 60 cents in the premarket session after the company said its subsidiary, Calando Pharma, has demonstrated systemic delivery of siRNA and the successful "silencing" of a widely recognized cancer gene via RNA interference (RNAi) in humans. The data were published in the Nature journal Sunday in an advance online edition, the company said. The 50-day average daily volume for Arrowhead is 126,000, according to the Nasdaq.

Helios & Matheson North America ( HMNA) should trade lower Monday after the software company said its relationship with Cogito, a fellow software company whose products Helios & Matheson markets, will be terminated. Helios & Matheson said it expects that future software product revenues, which it views as supplemental to its core consulting business, "will be significantly reduced in the short term." The 50-day average daily volume for Helios & Matheson is 62,000. The stock closed Friday at $1.65.

Verenium ( VRNM) may also lose ground Monday after the biofuels company received a "going concern" qualification from its auditors. The 50-day average daily volume for Verenium is 176,000. The stock closed Friday at $6.13.

China GengSheng Minerals ( CHGS) may trade higher Monday after the materials technology company said it has entered two new sales contracts totaling approx $1.56 mln (RMB10.65 million) for refractory products with two new customers. The average daily volume for China GengSheng is 244,000. Shares closed Friday at $2.73.

-- Written by Robert Holmes in Boston.

Check out all of Monday's high-volume, under-$5 stocks at the Dollar Store

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

If you liked this article you might like

Take a Look at These Stocks Poised to Trade Higher

These 5 Stocks Under $10 Could Explode Higher

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

The Worst Biopharma CEOs of 2016 Are ...